| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$408.7M | ROE | −123.08% |
| Net Margin | — | ROIC | — |
| Debt / Equity | 0.41 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Scholar Rock Holding Corporation is a biopharmaceutical company focused on spinal muscular atrophy and other rare, severe neuromuscular diseases. Its proprietary platform, based on understanding growth factor activation within the TGF-beta superfamily, develops monoclonal antibodies targeting the latent forms of growth factors. Lead candidate Apitegromab, a myostatin activation inhibitor, is in Phase 2 trials for SMA and FSHD, while SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 trial.
| Market Cap | $5.88B | Trading Days | 2052 |
| 52W High | 58.49 |
| 52W Low | 27.07 |
| % Off High | −16.12% |
| YTD | 11.37% | 1Y | 31.63% |
| 3Y | 590.99% | 5Y | 51.28% |
| Since incept. (ann.) | 15.12% |
| Ann. Volatility (1Y) | 62.30% | Ann. Volatility (3Y) | 221.42% |
| Sharpe (1Y) | 0.76 | Sharpe (3Y) | 0.72 |
| Max Drawdown (1Y) | −31.89% | Max Drawdown (3Y) | −65.21% |
| Beta (3Y, vs SPY) | −1.04 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CGON | CG Oncology, Inc. | $6.10B | — |
| TWST | Twist Bioscience Corp | $5.32B | — |
| IBRX | ImmunityBio, Inc. | $7.15B | — |
| CRSP | CRISPR Therapeutics AG | $4.59B | — |
| PCVX | Vaxcyte, Inc. | $7.65B | — |
| IMVT | Immunovant, Inc. | $7.93B | — |
| RGEN | REPLIGEN CORP | $7.97B | 164.2 |
| APGE | Apogee Therapeutics, Inc. | $8.14B | — |
| DBVT | DBV Technologies S.A. | $4.06B | — |
| KYMR | Kymera Therapeutics, Inc. | $8.66B | — |
| QGEN | QIAGEN N.V. | $9.07B | — |
| Denali Therapeutics Inc. |
| $3.79B |
| — |